Company Update
டீல்
டீல் மதிப்பு₹519 கோடி
டீல் vs வணிகம்Capex of Rs 519 Cr = 1.57x TTM revenue and 2.47x Net Worth
சொந்த வருவாயுடன் ஒப்பிடும் அளவு1.57×
செயல்படுத்தும் காலம்3.5 ஆண்டு
அடிப்படை தரம்A
AI முன்கணிப்புகள்
வருவாய் உயர்வு (முதல் ஆண்டு / நிலையான)0.0% / 130.0%
EPS உயர்வு125.0%
அப்சைடு பேஸ் / புல் / பேர்75.0% / 140.0% / -25.0%
கால எல்லை36-60 மாதங்கள்
உண்மையான சந்தைப் பதிவு
நுழைவு — அடுத்த நாள் தொடக்கம் (17 ஆக. 2026)₹137.8
சமீபத்திய முடிவு விலை (16 செப். 2026)₹148.3
தொடங்கியதிலிருந்து வருமானம்+7.6%
α vs Smallcap 250+10.0%
α vs சொந்தத் துறை90+ நாட்கள் வைத்திருந்த பிறகு மட்டுமே காட்டப்படும் — மருத்துவமனை இடைநிலை -8.7%, முதிர்ச்சியடைந்த 10 பரிந்துரைகளின் அடிப்படையில்
நேர்மறைகள்
- Transformational expansion adding 591 beds (+131% capacity increase) over 450 existing beds
- Geographic diversification beyond Trichy into high-demand Bengaluru market
- Outstanding recent operating momentum with Q1 FY27 revenue up 36.9% YoY and PAT up 107% YoY
- High return ratios with ROCE at 26.0% and OPM at 30.4%
- Substantial valuation re-rating headroom: TTM P/E of 36.2x vs peer median P/E of 94.8x
அபாயங்கள்
- Gestation drag and interest costs from term debt during FY28-FY29 construction/ramp-up phases
- Geographic concentration in Trichy, Tamil Nadu until Bengaluru facility matures
- Shortage of specialized medical practitioners or delays in doctor onboarding in Bengaluru
- Execution delays in constructing the 400-bed Trichy super-speciality block
முழு AI சுருக்கம்
1. ராம்ப்-அவேர் தாக்கக் கணக்கீடு
- Current Base: TTM Revenue = Rs 331 Cr, TTM PAT = Rs 57 Cr, TTM EPS = Rs 3.42, Net Worth = Rs 210 Cr, Existing Bed Capacity = 450 beds.
- Capex Announcement: Rs 519 Cr capex package to add 591 beds (+131% capacity expansion).
- Project 1: Bengaluru 91-bed leased facility (~Rs 33 Cr cost) expected by Q2 FY28.
- Project 2: Trichy Super-Speciality block (400 beds) + 100-bed floor additions (~Rs 486 Cr total cost) commissioned between Q2 FY28 and Q2 FY30.
- Execution Timeline: Phased rollout over 2.5 to 4 years (FY28 to FY30), with bed occupancy ramping to steady state over FY30-FY32.
- Revenue Uplift Math:
- Year 1 (FY27): 0.0% uplift from this capex (construction phase).
- Year 2 (FY28): Initial ~15-20% uplift as Bengaluru asset-light block opens.
- Steady State (FY31/FY32): Added 591 beds operating at 65% occupancy will add ~Rs 420-450 Cr in annual revenue (+130% over current TTM revenue).
- EPS Uplift Math: High initial interest and depreciation costs during FY28 will temper margins, but at steady-state occupancy (FY31), operating leverage will lift overall PAT to ~Rs 125-135 Cr (+125% EPS uplift).
2. Industry Context & Quality Assessment
- Capital Intensity: HIGH. Tertiary healthcare expansion requires massive upfront asset creation and advanced medical tech equipment.
- Execution Difficulty: Moderate to High. Success requires hiring specialized clinical teams (e.g., organ transplant, neuro sciences) and driving bed occupancy from 30% to 65%+ over 3 years.
- Industry Growth: Indian hospital sector is expected to grow at 12-15% CAGR driven by rising medical insurance and demand for high-end tertiary care.
- Quality Profile: Strong fundamental standing. ROCE is 26.0%, OPM is 30.4%, and promoter holding stands firmly at 75.0% without pledges.
3. Valuation & Multibagger Potential
- Current Valuation: KMC trades at a trailing P/E of 36.2x, significantly below the peer median P/E of 94.8x.
- Re-rating Engine: The operational expansion from a single-city hospital chain to a regional multi-city player (entering Bengaluru) combined with a doubling of bed capacity provides dual drivers: structural earnings expansion and valuation re-rating.
4. சூழ்நிலைப் பகுப்பாய்வு
- Bull Case (+140%): Smooth commissioning of Bengaluru and Trichy blocks by FY29; rapid ramp-up to 70% occupancy; P/E re-rates toward peer median (~55-60x target PE).
- Base Case (+75%): Phased completion by FY30 with minor delays; steady-state occupancy achieved by FY32; moderate P/E re-rating to ~45x on expanded earnings base.
- Bear Case (-25%): Delay in Trichy project completion, margin contraction due to high debt service costs, and slower-than-expected doctor recruitment in Bengaluru.
5. தீர்ப்பின் காரணம்
KMC Speciality exhibits exceptional operating performance (Q1 FY27 net profit +107% YoY) backed by 26% ROCE and 75% promoter holding. The Rs 519 Cr capex plan represents a clear, high-impact growth catalyst. While execution will take 3-5 years to fully mature, the sheer scale of expansion (+131% capacity) and attractive relative valuation make KMC a STRONG_CANDIDATE for multibagger returns over a 3-5 year horizon.
2026-08-14 நிலவரப்படி பகுப்பாய்வு (விலை ₹123.85) · AI ஆய்வு, முதலீட்டு ஆலோசனை அல்ல.
பின்தொடர்Telegram
